Trust Guideline for the Use of Parenteral Vancomycin and Teicoplanin in Adults
|
|
- Alexia Owens
- 5 years ago
- Views:
Transcription
1 A clinical guideline recommended for use: In: By: For: Division responsible for document: Key words: Names of document authors: Job titles of document authors: Name of document author s Line Manager: Job title of author s Line Manager: Assessed and approved by: All clinical areas where Vancomycin or Teicoplanin is prescribed (excluding critical care complex and theatres) All medical, nursing, pharmacy, microbiology and phlebotomy staff All adult patients receiving Vancomycin, Teicoplanin Trustwide Vancomycin, Teicoplanin, therapeutic drug monitoring, Intravenous, intramuscular Caroline Hallam and Dawn Whitbourn Specialist Pharmacists, Antimicrobial Therapy Helen Williams Consultant Microbiologist Antimicrobial Subcommittee on behalf of the Clinical Guidelines Assessment Panel (CGAP) approved by CGAP chair Reported as approved to the: Clinical Standards Group and Effectiveness Sub-board Date of approval: 16/03/2017 To be reviewed before: 13/01/2019 To be reviewed by: Authors Reference and/or Trustdocs ID No: CA2030 V6.1 ID No: 1192 Version No: 6.2 Description of changes: Compliance links: (is there any NICE related to guidance) If Yes does the strategy/policy deviated from the recommendations of NICE? If so, why? Further amendment to Teicoplanin dose in renal impairment None N/A This guideline has been approved by the Trust's Clinical Guidelines Assessment Panel as an aid to the diagnosis and management of relevant patients and clinical circumstances. Not every patient or situation fits neatly into a standard guideline scenario and the guideline must be interpreted and applied in practice in the light of prevailing clinical circumstances, the diagnostic and treatment options available and the professional judgement, knowledge and expertise of relevant clinicians. It is advised that the rationale for any departure from relevant guidance should be documented in the patient's case notes. The Trust's guidelines are made publicly available as part of the collective endeavour to continuously improve the quality of healthcare through sharing medical experience and knowledge. The Trust accepts no responsibility for any misunderstanding or misapplication of this document. Available via Trust Docs Version: 6.2 Trust Docs ID: 1192 Page 1 of 11
2 CONTENTS - Vancomycin 1. Quick Reference Guide Page 3 2. Prescribing the Initial Maintenance Dose Page 4 3. Taking Levels and Ongoing Monitoring Page 5 4. Administration Details for Vancomycin Page 6 5. Renal Patients (CrCl < 20mL/min or Dialysis Page 6 (peritoneal and haemo-) patients) -Teicoplanin 1. Administration Details for Teicoplanin Page 8 2. Intramuscular Teicoplanin Page 8 3. Prescribing Loading and Maintenance Doses Page 9 and Monitoring of Teicoplanin - Background Information Page Available via Trust Docs Version: 6.2 Trust Docs ID: 1192 Page 2 of 11
3 Vancomycin Table 1: Vancomycin Quick Reference Guide CrCl > 110mL/min CrCl mL/min CrCl 60 90mL/min CrCl 20-60mL/min CrCl <20mL/min or dialysis 1.5 grams BD 1.25 grams BD 1 gram BD 1 gram OD 1 gram STAT Trough level pre 3 rd or 4 th dose Trough level pre 3 rd or 4 th dose Trough level pre 3 rd or 4 th dose Trough level pre 2 nd dose Level after 24 hours Give next dose and when levels reported adjust dosing (see table below) Give next dose and when levels reported adjust dosing (see table below) Give next dose and when levels reported adjust dosing (see table below) Give next dose and when levels reported adjust dosing (see table below) After dose adjustment check levels pre 3 rd new dose After dose adjustment check levels pre 3 rd new dose After dose adjustment check levels pre 3 rd new dose After dose adjustment check levels pre 2 nd new dose When levels in range (10-15mg/L general infections or 15-20mg/L severe infections and bone and joint infections) monitor pre dose levels every 3-4 days For further information please see below. Await level Level <15mg/L Give dose and check level in 24 hours/at each HD session. Level 15-25mg/L Hold dose and recheck level in 24 hours/at each HD session. Level >25mg/L Hold dose and recheck level in 48 hours/at each HD session Available via Trust Docs Version: 6.2 Trust Docs ID: 1192 Page 3 of 11
4 Follow instructions below 1) Prescribing the Initial Maintenance Dose 2) Taking levels and Ongoing Monitoring NB: for renal patients (CrCl < 20mL/min or dialysis (peritoneal and haemo-) patients), go to pg 6 1. Prescribing the Initial Maintenance Dose Table 2: Initial maintenance dose Dose Frequency CrCl >110mL/min 1.5g 12 hourly CrCl mL/min 1.25g 12 hourly CrCl 60 90mL/min 1g 12 hourly CrCl 20 60mL/min 1g 24 hourly Calculate the patients Creatinine Clearance if patient has impaired renal function a. Calculate the patient s creatinine clearance (CrCl) using the Cockcroft-Gault equation. Click here for the Cockcroft & Gault Calculator or use the calculation below: CrCl (ml/min) = F (140-age) x weight (kg) Serum creatinine (micromols/l) F = 1.04 for females, 1.23 for males Use actual body weight or ideal body weight, whichever is lower Ideal body weight (kg): Men = 50 + (2.3 x no. of inches over 5 ft.) Women = (2.3 x no. of inches over 5 ft.) In patients with low creatinine (<60micromol/L), use 60micromol/L. Do not use egfr 2. Taking Levels and Ongoing Monitoring Available via Trust Docs Version: 6.2 Trust Docs ID: 1192 Page 4 of 11
5 a) Take a pre-dose (trough) level pre 3 rd or 4 th dose if 12 hourly dosing or pre 2 nd dose for 24 hourly dosing. b) If the renal function is stable, give the next dose before the trough result is available. If the renal function is deteriorating, withhold until the result is available and follow advice in table 2. Please discuss with microbiology/pharmacy if further advice is needed. c) Interpret levels as below. If the trough is within the normal range and renal function remains stable repeat trough level every 3-4 days. If the renal function is unstable, daily levels are required. Table 3: Adjustment of Vancomycin Dosage Regimen Pre dose Level <10mg/L 10-15mg/L Recommendation Below therapeutic range increase the dose by 50% or consider reducing the dosage interval or seek advice. If patient is responding, maintain the present dosage regimen. If the patient is seriously ill, consider increasing the dose amount or reducing the dosage interval to achieve trough of 15-20mg/L mg/L Within target range for treatment of severe infections (bacteraemia, infective endocarditis, osteomyelitis, meningitis, pneumonia and severe skin and soft tissue infections e.g. necrotising fasciitis). Maintain present dosage regimen. If treating less severe infections, a pre-dose level of 15-20mg/L is acceptable so maintain present dosage regimen. >20 mg/l Dose reduction or increase in dosing interval necessary. NB it may be necessary to increase the dose up to 1.5g 12 hourly in patients with good renal function and low levels. a) Levels should rarely be required between 5.00pm and 9.00am as dosing regimens allow for the vast majority of assays to be performed between 9.00 am and 5.00pm. b) Always check the dosage history and sampling time are appropriate before interpreting the result. Available via Trust Docs Version: 6.2 Trust Docs ID: 1192 Page 5 of 11
6 3. Administration Details for Vancomycin: Reconstitute each 500mg vancomycin with 10mLs of water for injection and add to 5% glucose or 0.9% sodium chloride infusion fluid so that the final concentration is no greater than 500mg per 100mL. Each 500mg must be administered over at least fifty minutes ie 1g over 100 mins and 1.5g (rarely required) over 150 mins. If this rate is exceeded red-neck/red-man syndrome, pain or muscle spasm can result. Nurses should state on the drug chart the exact time of administration to facilitate the accurate interpretation of levels. 4. Renal patients (CrCl < 20mL/min or dialysis (peritoneal and haemo-) patients) 1. Maintenance Dose in Renal Patients The maintenance dose to be administered as follows: 1g Vancomycin in 250ml 0.9% sodium chloride over 2 hours 2. Sampling A blood sample for a Vancomycin serum concentration should be taken after 24 hours for non-dialysis/peritoneal dialysis patients and at the start of each subsequent haemodialysis sessions for haemodialysis patients. Notes: Samples taken from dialysis patients should be labelled as urgent before sending to the lab Larger loading doses of vancomycin can be administered during dialysis so to avoid causing delays Vancomycin is NOT dialysed Table 4: Interpretation of Vancomycin levels in Renal Patients Vancomycin level Action <15mg/L Give a further dose of Vancomycin. Recheck levels in 24 hours for non-dialysis/pd patients Recheck levels just before the start of the next dialysis session for haemodialysis patients 15-25mg/L Do not give a further dose. Recheck levels in 24 hours for non-dialysis/pd patients and at each dialysis session for HD patients >25mg/L Do not give a further dose. Recheck levels in 48 hours for non-dialysis/pd patients and at each dialysis session for HD patients Available via Trust Docs Version: 6.2 Trust Docs ID: 1192 Page 6 of 11
7 INTRAVENOUS (IV) VANCOMYCIN FOR HAEMODIALYSIS PATIENTS Standard Flux Dialyser Vancomycin can be given post, or start from last hour of dialysis Give a stat dose of 1 gram in 250mL 0.9% sodium chloride Take pre-dialysis vancomycin level If level < 15mg/L give a repeat stat dose of 1 gram in 250mL 0.9% sodium chloride Available via Trust Docs Version: 6.2 Trust Docs ID: 1192 Page 7 of 11
8 Teicoplanin Patients should receive a teicoplanin loading dose (based on ACTUAL body weight see below) to ensure optimum drug levels in the blood are achieved as rapidly as possible. After the loading dose, a maintenance dose should be prescribed once daily (based on renal function / ACTUAL body weight - see below). The dose depends on the indication (refer to 3 tables below) The monitoring requirements depend on the indication and duration. Levels are usually only required for deep seated infections requiring an extended course of teicoplanin beyond 5-7 days Administration Details for Teicoplanin Reconstitute with water for injection provided. Give by IV bolus over 3-5 minutes or infuse over 30 minutes. The reconstituted solution may be injected directly, or alternatively diluted with a convenient volume of 0.9% Sodium Chloride or 5% Glucose if given by infusion. Teicoplanin can also be given by intramuscular injection (see below). Intramuscular Teicoplanin There are some specific situations where IM teicoplanin is recommended e.g. patients with no IV access and the treatment of outpatients with diabetic foot infections. Occasionally, IM teicoplanin is indicated in other patients where they require a glycopeptides and IV access is impossible or inappropriate. Available via Trust Docs Version: 6.2 Trust Docs ID: 1192 Page 8 of 11
9 1. Prescribing Loading and Maintenance Doses & Monitoring of Teicoplanin Table 5: Complicated skin and soft tissue infections, pneumonia, complicated urinary tract infections Loading Dose Maintenance Dose Renal impairment Levels Under 70kg: 400mg bd every 12 hours for 3 doses Over 70kg 6mg/kg every 12 hours for 3 doses Under 70kg: 400mg od Over 70kg: 6mg/kg od Dose adjustment required from 4 th day of treatment. CrCL* 30-80: Dose as in normal renal function then reduce dose after 4 th day to half of the dose daily or normal dose every 48 hours CrCL*<30mL/min and in haemodialysis: Dose as in normal renal function, then reduce dose after 4 th day to 30% of the dose daily or normal dose every 72 hours If the duration of therapy is expected to be <5 days then no monitoring is required. If the duration of therapy is expected to be longer then take a trough level at day 3-5. Therapeutic Range: 10mg/L-60mg/L Table 6: Bone and Joint Infections Loading Dose Maintenance Dose Renal impairment Levels 10mg/kg every 12 hours for 3 administrations 10mg/kg IV od Dose adjustment required from 4 th day of treatment. CrCL* 30-80: Dose as in normal renal function then reduce dose after 4 th day to half of the dose daily or normal dose every 48 hours CrCL*<30mL/min and in haemodialysis: Dose as in normal renal function, then reduce dose after 4 th day to 30% of the dose daily or normal dose every 72 hours Target trough level at 3-5 days, then once a week during maintenance Therapeutic Range: >20mg/L-60mg/L Table 7: Endocarditis Loading Dose Maintenance Dose Renal impairment Levels 10mg/kg every 12 hours for 3 administrations 10mg/kg IV or IM od Dose adjustment required from 4 th day of treatment. CrCL* 30-80: Dose as in normal renal function then reduce dose after 4 th day to half of the dose daily or normal dose every 48 hours CrCL*<30mL/min and in haemodialysis: Dose as in normal renal function, then reduce dose after 4 th day to 30% of the dose daily or normal dose every 72 hours Target trough level at 3-5 days, then once a week during maintenance Therapeutic Range: >20mg/L-60mg/L * Click here for the Cockcroft & Gault Calculator or use the calculation below: Use actual body weight or ideal body weight whichever is lower *CrCl (ml/min) = F (140-age) x weight (kg) Ideal body weight (kg): Men = 50 + (2.3 x no. of inches over 5 ft.) Serum creatinine (micromols/l) F = 1.04 for females, 1.23 for males Women = (2.3 x no. of inches over 5 ft.) In patients with low creatinine (<60micromol/L), use 60micromol/L. Do not use egfr Available via Trust Docs Version: 6.2 Trust Docs ID: 1192 Page 9 of 11
10 Background: Vancomycin and teicoplanin are glycopeptide antimicrobials. They are essential and invaluable in the management of infections due to Methicillin-Resistant Staphylococcus aureus (MRSA), Coagulase-negative Staphylococci and other gram positive microorganisms in penicillin allergic patients. Resistance to glycopeptides in Staphylococcus species and Enterococcus species has been reported and has serious implications for patient care. It is therefore imperative that vancomycin and teicoplanin are used prudently by clinicians and this will ensure that patients receive maximum benefit from these agents while ensuring resistance and side effects are minimised. Indications for Use: Vancomycin and teicoplanin should only be prescribed where a glycopeptide antibiotic is specifically required or recommended. Both drugs are potentially ototoxic and nephrotoxic, though teicoplanin is associated with a lower incidence of toxicity than vancomycin. The risk of toxicity increases with prolonged use (>3 weeks), high plasma concentration, concomitant use of aminoglycosides and loop diuretics. All patients on vancomycin require plasma vancomycin measurement. Plasma teicoplanin levels are required depending on the indication and duration of treatment. Vancomycin levels can be measured in the Trust, whereas teicoplanin levels can be measured in only one laboratory in the UK (Bristol). Therefore in patients where knowledge of therapeutic or toxic levels is critical, vancomycin is preferable. Teicoplanin may be preferable in patients where levels are not deemed necessary, particularly if difficult to bleed, and in patients who will be transferred to outpatient antimicrobial therapy (OPAT). Teicoplanin can be administered intramuscularly, for example in the management of outpatients with diabetic foot infections and inpatients with no intravenous access. For advice on whether vancomycin or teicoplanin are appropriate antibiotics please consult the following resources via the trust intranet. Trust Antibiotic Policy for the Management of Common Infections in Adults with General Medicine and Surgery (CA4022v9) Trust Guideline for the Management of Antibiotic Prophylaxis in Adults undergoing Surgery (CA2096V2) Further advice During working hours contact microbiology on extension 4587 or 4589, your ward pharmacist or pharmacy medicines information on extension 3139 or bleep Out of hours contact the on call microbiologist (bleep via switchboard) or on call pharmacist (bleep via switchboard). Available via Trust Docs Version: 6.2 Trust Docs ID: 1192 Page 10 of 11
11 Summary of development and consultation process undertaken before registration and dissemination The authors listed above drafted this guideline on behalf of the antimicrobial subcommittee who have agreed the final content. During its development the guideline has been circulated for comment to the microbiologists. Comments were addressed and incorporated if appropriate. This version has been endorsed by the Clinical Guidelines Assessment Panel. Distribution list/dissemination method All Microbiologists via Dr Williams, all wards via ward pharmacists, medical staff via Trust intranet. All pharmacists via Caroline Hallam/Dawn Whitbourn. References/source documents - AH Thomson et al, Development and evaluation of vancomycin dosage guidelines designed to achieve new target concentrations, Journal of Antimicrobial Chemotherapy, 63: (2009) - MJ Rybak et al, Vancomycin Therapeutic Guidelines: A Summary of Consensus Recommendations from the Infectious Disease Society of America, the American Society of Health-System Pharmacists and the Society of Infectious Disease Pharmacists, Clinical Infectious Diseases, 49: (2009) - British National Formulary March 2014 Available via Trust Docs Version: 6.2 Trust Docs ID: 1192 Page 11 of 11
Full title of guideline INTRAVENOUS VANCOMYCIN PRESCRIBING AND MONITORING GUIDELINE FOR ADULT PATIENTS. control
Full title of guideline Author: Contact Name and Job Title Division and specialty Scope Explicit definition of patient group to which it applies (e.g. inclusion and exclusion criteria, diagnosis) Changes
More informationJoint Trust Guideline for the Use of Intravenous Vancomycin in Paediatrics
A clinical guideline recommended For use in: All clinical areas where vancomycin is prescribed for Children aged 1 month to 16 years By: All medical, nursing, pharmacy, microbiology and phlebotomy paediatric
More informationClinical Guidelines for Use of Antibiotics. VANCOMYCIN (Adult)
VANCOMYCIN (Adult) Please always prescribe VANCOMYCIN in the Variable Dose Antibiotic section of the EPMA SUPPLEMENTARY drug chart (and add a placeholder on the electronic drug chart). 1 Background Vancomycin
More informationINTRAVENOUS VANCOMYCIN PRESCRIBING AND MONITORING GUIDELINE FOR ADULT PATIENTS
Title of guideline (must include the word Guideline (not protocol, policy, procedure etc) INTRAVENOUS VANCOMYCIN PRESCRIBING AND MONITORING GUIDELINE FOR ADULT PATIENTS Author: Contact Name and Job Title
More informationNHS Grampian Staff Guidance for the Administration of Intravenous Vancomycin in Adults via Intermittent (pulsed) Infusion
Acute Sector NHS Grampian Staff Guidance for the Administration of Intravenous Vancomycin in Adults via Intermittent (pulsed) Infusion Co-ordinators: Gillian Macartney Fiona McDonald Specialist Antibiotic
More informationGuideline for the Management of Continuous IV Vancomycin Infusion in Neonates on NICU A Clinical Guideline recommended for use
Guideline for the Management of Continuous IV Vancomycin Infusion in A Clinical Guideline recommended for use For Use in: By: For: Division responsible for document: Key words: Name and job title of document
More informationUse ideal body weight (IBW) unless actual body weight is less. Use the following equation to calculate IBW:
Amikacin is a partially restricted (amber) antibiotic for the treatment of infections due to gentamicin resistant Gram negative bacilli or as advised by microbiology. As with other aminoglycosides, therapeutic
More informationA Clinical Guideline for the use of Intravenous Aminophylline in Acute Severe Asthma in Children
For Use in: By: For: Division responsible for document: Key words: Name and job titles of document author: Name and job title of document author s Line Manager: Supported by: Assessed and approved by the:
More informationIV Vancomycin dosing and monitoring Antibiotic Guidelines. Contents. Intro
IV Vancomycin dosing and Antibiotic Guidelines Classification: Clinical Guideline Lead Author: Antibiotic Steering Committee Additional author(s): as above Authors Division: DCSS & Tertiary Medicine Unique
More informationGuideline for the Use of Granulocyte Colony Stimulating Factor (G-CSF) for Adults in Oncology and Haematology
(G-CSF) for Adults in Oncology and Haematology For Use in: By: Oncology and Haematology Inpatients and Outpatients Oncologists and Haematologists For: Division responsible for document: Key words: Name
More informationGlucocorticoid replacement, Steroids, Acute Illness Dr Rupa Ahluwalia, Consultant Physician (NNUH)
For Use in: By: For: Division responsible for document: Key words: Name and job title of document author s: Name and job tile of document author s Line Manager: Supported by: Assessed and approved by the:
More informationTrust Protocol for the Administration of Intravenous Methylprednisolone for Thyroid Eye Disease A Protocol. The Clinical Investigation Unit (CIU)
A Protocol For Use in: By: For: Division responsible for document: Key words: Name of document author: Job title of document author: Name and job title of document author s Line Manager: Supported by:
More informationTrust Guideline for the Management of: Condition or Procedure in Adults and / or Children
Trust Guideline for the Management of: Condition or Procedure in Adults and / or Children A clinical guideline recommended For use in: By: For: Division responsible for document: Key words: Name of document
More informationDivision 2, Surgical and Anaesthetics Directorates All surgical and anaesthetics staff Patients with an implanted spinal cord stimulator For:
Joint Clinical Guideline for Patients with an implanted spinal cord stimulator (SCS) For Use in: Division 2, Surgical and Anaesthetics Directorates By: All surgical and anaesthetics staff Patients with
More informationBy: For: Division responsible for document: Key words: Name and job title of document author: Name and job title of document author s Line Manager:
For Use in: By: For: Guidelines for the Management of Interruption of Biologic Therapies for Division responsible for document: Key words: Name and job title of document author: Name and job title of document
More informationTrust Guideline for the inclusion of women at High Risk of Breast Cancer in the NHS Breast Screening Programme
Trust Guideline for the inclusion of women at High Risk of Breast Cancer in the NHS Breast Screening Programme For Use in: By: For: Division responsible for document: Key words: Name and job title of document
More informationTrust Guideline for the Management of: Abnormal Pre-operative Thyroid Function Tests in Adults. Anaesthetists Abnormal Pre-op Thyroid Function Test
For Use in: By: For: Pre-operative Thyroid Function Tests in Adults Division responsible for document: Key words: Name and job titles of document author: Name and job title of document author s Line Manager:
More informationPolicy: Created: 2/11/2015; Approved: Adult Pharmacokinetic Dosing and Monitoring- Vancomycin Dosing
ProMedica Health System Clinical Interdepartmental Policy and Procedure: Section: Policy: Date: Subject: Pharmacy Created: 2/11/2015; Approved: Adult Pharmacokinetic Dosing and Monitoring- Vancomycin Dosing
More informationTrust Guideline for the Management of Patient Controlled Analgesia (PCA) in Adults
Patient Controlled Analgesia (PCA) in Adults A clinical guideline recommended for use For Use in: In all Clinical Areas By: Anaesthetists, Ward Nurses, Recovery Staff Acute Pain Service Staff For: Adult
More information(Max 2 g) = to nearest 250 mg
Appendix 1 (part 1 of 8): Rubric for competency assessment of pharmacists prescribing and managing vancomycin Empiric Dosing Phase Pts Yes No Data Error OP Did the pharmacist document the indication 2
More informationJoint Trust Guideline for the Management of Methylprednisolone Sodium Succinate Infusion for Child or Young Person A Clinical Guideline
A Clinical Guideline For Use in: Children s Department By: Registered Paediatric Nurses and Medical Staff Children with active inflammatory bowel disease, For: active rheumatological conditions or other
More informationTrust Guideline for the Prevention of Tuberculosis and Management of Tuberculosis Exposure in Health Care Workers
A Clinical Guideline For Use in: By: For: Division responsible for document: Key words: Name and job title of document author: Name and job title of document author s Line Manager: Supported by: Assessed
More informationVANCOMYCIN DOSING AND MONITORING GUIDELINES
VANCOMYCIN DOSING AND MONITORING GUIDELINES NB Provincial Health Authorities Anti-Infective Stewardship Committee Approved: May 2017 GENERAL COMMENTS Vancomycin is a glycopeptide antibiotic with bactericidal
More informationStRs and CT doctors in haematology. September Folinic acid dose modified.
High dose Methotrexate and folinic acid rescue Full Title of Guideline: Author (include email and role): Division & Speciality: Clinical Guideline Review Date September 2018 GUIDELINE FOR THE USE OF HIGH
More informationEDUCATIONAL COMMENTARY VANCOMYCIN MONITORING
EDUCATIONAL COMMENTARY VANCOMYCIN MONITORING Commentary provided by: Julie Hall, MHS, MT (ASCP) Assistant Dean, College of Health Professions Assistant Professor, Medical Laboratory Science Grand Valley
More informationCubicin A Guide to Dosing
Cubicin A Guide to Dosing Cubicin (Daptomycin) powder for solution for injection or infusion Indications (see SmPC) 1 : Cubicin is indicated for the treatment of the following infections (see sections
More informationAdult Institutional Pharmacokinetics Protocol
Adult Institutional Pharmacokinetics Protocol Policy Title: Clinical Pharmacokinetics (PK) Service Policy Policy Statement: It is the policy of UMHC that PK consult orders (for vancomycin or aminoglycosides)
More informationD DAVID PUBLISHING. 1. Introduction. Kathryn Koliha 1, Julie Falk 1, Rachana Patel 1 and Karen Kier 2
Journal of Pharmacy and Pharmacology 5 (2017) 607-615 doi: 10.17265/2328-2150/2017.09.001 D DAVID PUBLISHING Comparative Evaluation of Pharmacist-Managed Vancomycin Dosing in a Community Hospital Following
More informationGENTAMICIN: GUIDELINES FOR ONCE DAILY USAGE IN ADULT AND PAEDIATRIC SETTINGS GENTAMICIN: GUIDELINES FOR ONCE DAILY USAGE IN ADULT AND PAEDIATRIC
GENTAMICIN: GUIDELINES FOR ONCE DAILY USAGE IN ADULT AND PAEDIATRIC SETTINGS 1 1 Gentamicin: Guidelines for Once Daily Usage in Adult and Paediatric Settings These guidelines were designed by the Gentamicin
More informationVancomycin: Class: Antibiotic.
Vancomycin: Class: Antibiotic. Indications: Treatment of patients with infections caused by staphylococcal species and streptococcal Species. Available dosage form in the hospital: 1G VIAL, 500MG VIAL.
More informationTrust Guideline for the Management of: Adult patients requiring anticoagulation with Warfarin (including reversal)
(including reversal) A Clinical Guideline recommended for use: For Use in: By: For: Division responsible for document: Key words: Name and job title of document author: Name and job title of document author
More informationHaemodialysis central venous catheter-related sepsis management guideline Version 3. NAME M. Letheren Chair Clinical Effectiveness Advisory Group
Lancashire Teaching Hospitals NHS Foundation Trust Haemodialysis central venous catheter-related sepsis management guideline Version 3 AUTHOR APPROVED BY DATE AUTH REF. NO NAME REBG/00018/July12 Michael
More informationTDM of Aminoglycoside Antibiotics
TDM Lecture 3 5 th Stage TDM of Aminoglycoside Antibiotics The aminoglycoside antibiotics are widely used for the treatment of gram-negative infections, often in combination with a β-lactam antibiotic
More informationBSWH Pharmacist Continuing Education PART 5: Pharmacotherapy and Pharmacokinetics in Adults: Aminoglycosides and Vancomycin
BSWH Pharmacist Continuing Education 2015 PART 5: Pharmacotherapy and Pharmacokinetics in Adults: Aminoglycosides and Vancomycin Objectives Define basic pharmacodynamic and pharmacokinetic principles Describe
More informationECN Protocol Book. Generic Chemotherapy Protocol Guidelines. ECN_Protocol_Book_generic chemotherapy protocol guidelines guidelines_1
ECN Protocol Book Generic Chemotherapy Protocol Guidelines Name of person presenting document: Reason for document development: Names of development team: Specify groups of staff to whom the document relates:
More informationAntimicrobial Reference Laboratory
Antimicrobial Reference Laboratory GUIDELINE RANGES FOR TDM 2016-17 Andrew Lovering Antimicrobial Reference Laboratory North Bristol NHS Trust Southmead Hospital Bristol, BS10 5NB UK Aminoglycosides Gentamicin
More informationNorth Derbyshire OPAT (Outpatient Parenteral Antimicrobial Therapy) Pathway for Primary Care (Step-Up Pathway/Admission Avoidance)
North Derbyshire OPAT (Outpatient Parenteral Antimicrobial Therapy) Pathway for Primary Care (Step-Up Pathway/Admission Avoidance) Introduction OPAT services provide intravenous (IV) antibiotics to patients
More informationVancomycin Drug Class 1
Drug Class 1 Antibiotic glycopeptide Spectrum 1 Cross Sensitivities / Allergies 1 Refer to product monograph for complete spectrum Gram positive pathogens (e.g., S. aureus, Enterococcus, S. viridans, methicillinresistant
More information(telavancin) Healthcare Professional s Guide. Version 2, 4 November 2014
VIBATIV (telavancin) Healthcare Professional s Guide Version 2, 4 November 2014 1 Table of Contents Introduction... 3 About Vibativ / Therapeutic indications... 3 Antimicrobial spectrum of activity for
More informationInfective Endocarditis Empirical therapy Antibiotic Guidelines. Contents
Infective Endocarditis Empirical therapy Antibiotic Guidelines Classification: Clinical Guideline Lead Author: Antibiotic Steering Group Additional author(s): as above Authors Division: Division of Clinical
More informationD DAVID PUBLISHING. Evaluation of the Effectiveness of a Vancomycin Nomogram at Predicting Trough Levels within a Therapeutic Range. 1.
Journal of Pharmacy and Pharmacology 2 (2014) 713-721 doi: 10.17265/2328-2150/2014.12.004 D DAVID PUBLISHING Evaluation of the Effectiveness of a Vancomycin Nomogram at Predicting Trough Levels within
More informationTrust Guideline for the Management and Administration of Intravenous Iron in Adults under the Gastroenterology Directorate
A clinical guideline recommended for use For Use in: The Gastroenterology Directorate By: Registered nurses competent in the administration of intravenous therapy and medical staff For: Adult patients
More informationEssential Shared Care Agreement (South Staffordshire): Aciclovir Administration in the Community
E088 Essential Shared Care Agreement (South Staffordshire): Aciclovir Administration in the Community Patient s name: DOB NHS Number Patient s address: Consultant Note: Shared care agreement sets out a
More informationAMINOGLYCOSIDES TDM D O N E B Y
AMINOGLYCOSIDES TDM DONE BY: SARA ALARFAJ 2014 OUTLINE Introduction about Aminoglycosides. Spectrum/uses. TDM Aminoglycosides TDM Pharmacodynamics Pharmacokinetics. Dosing in AG. Sampeling time and Monitoring.
More informationJoint Trust Clinical Guideline for Monitoring of patients with Guillain Barré Syndrome (GBS)
A Clinical Guideline For Use in: By: For: Division responsible for document: Key words: Name of document author: Job title of document author: Name of document author s Line Manager: Job title of author
More informationCLINICAL USE OF GLYCOPEPTIDES. Herbert Spapen Intensive Care Department University Hospital Vrije Universiteit Brussel
CLINICAL USE OF GLYCOPEPTIDES Herbert Spapen Intensive Care Department University Hospital Vrije Universiteit Brussel Glycopeptides Natural Vancomycin introduced in 1958 Teicoplanin introduced in Europe
More informationAntimicrobial Reference Laboratory
Antimicrobial Reference Laboratory GUIDELINE RANGES FOR TDM 2018 Andrew Lovering Antimicrobial Reference Laboratory North Bristol NHS Trust Southmead Hospital Bristol, BS10 5NB Guideline Ranges 2018 Aminoglycosides
More informationAdult Inpatient Antibiogram. Antimicrobial Susceptibilities of Frequently Recovered Clinical Isolates. January to December 2016
Adult Inpatient Antibiogram Antimicrobial Susceptibilities of Frequently Recovered Clinical Isolates January to December 2016 Department of Pathology Camille Hamula, PhD Director, Clinical Microbiology
More informationSBUH Aminoglycoside Dosing Protocol
Adult Aminoglycoside Dosing for Gram negative infections prior to available serum levels (Excludes patients with cystic fibrosis, OB GYN patients and surgical prophylaxis) Cr Cl 40 ml/min 5 7 mg/kg INT
More informationGemcitabine + Cisplatin Regimen
Gemcitabine + Cisplatin Regimen Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby out-patient Indication
More informationA Trust Guideline for the Management of. Bronchiolitis in Infants and Children under the age of 24 months
A Clinical Guideline recommended Children s Assessment Unit (CAU), Buxton Ward, For use in: Children s Day Ward, Jenny Lind Out-patients Department, Accident and Emergency Department By: Medical and Nursing
More informationAntimicrobial Guidelines for the Empirical Management of Diabetic Foot Infections
Antimicrobial Guidelines for the Empirical Management of Diabetic Foot Infections Version 7.2 PAGL Inclusion Approved at January 2017 PGC APPROVED BY: TRUST REFERENCE: B3/2017 AWP REF: UHL Policies and
More informationBACKGROUND Measuring renal function :
A GUIDE TO USE OF COMMON PALLIATIVE CARE DRUGS IN RENAL IMPAIRMENT These guidelines bring together information and recommendations from the Palliative Care formulary (PCF5 ) BACKGROUND Measuring renal
More informationIMPROVING VANCOMYCIN DOSING AND MONITORING IN THE ABSENCE OF A FORMAL PHARMACOKINETIC SERVICE:
IMPROVING VANCOMYCIN DOSING AND MONITORING IN THE ABSENCE OF A FORMAL PHARMACOKINETIC SERVICE: IMPACT OF A PHARMACY DEPARTMENT-WIDE APPROACH IN A COMMUNITY HOSPITAL SETTING November 2014 Monica Dorobisz,
More informationJoint Trust Guideline for 72 hour fast for investigation of spontaneous hypoglycaemia in adults For use in:
For use in: Cringleford & Langley Wards & Clinical Investigation Unit By: Registered nurses and medical staff on Cringleford & Langley Wards For: Adult patients suspected of having spontaneous hypoglycaemia
More informationMANAGEMENT OF HAEMODIALYSIS CATHETER RELATED BLOOD STREAM INFECTION
MANAGEMENT OF HAEMODIALYSIS CATHETER RELATED BLOOD STREAM INFECTION RRCV CMG Renal and Transplant Service 1. Introduction Catheter related blood stream infection (CR-BSI) is a common complication in patients
More informationEffect of piperacillin/tazobactam restriction on usage and rates of acute renal failure
Journal of Medical Microbiology (2016), 65, 195 199 DOI 10.1099/jmm.0.000211 Effect of piperacillin/tazobactam restriction on usage and rates of acute renal failure Michael A. Lorenz, 1,2 Ryan P. Moenster
More informationRenal Unit. Catheter Related Bacteraemia Guidelines
Renal Unit Policy Manager Drew Henderson Policy Group Renal Unit Policy Established 21/01/2014 Policy Review Period/Expiry 21/01/2015 Last Updated 21/01/2014 This policy does apply to Medical/Dental Staff
More informationconcentrate intravenous solution and other strong potassium solutions
Policy for the use of potassium chloride concentrate intravenous solution and other strong potassium solutions CLINICAL GUIDELINES ID TAG Policy for the use of potassium chloride Title: concentrate intravenous
More informationSHC Vancomycin Dosing Guide
SHC Vancomycin Dosing Guide A: Initial dosing considerations B. Pharmacodynamic Targets: goal AUC and troughs C. Loading dose D: Initial Vancomycin Maintenance Dosing and Serum Concentration Monitoring
More informationClinical Study Prospective Trial of a Novel Nomogram to Achieve Updated Vancomycin Trough Concentrations
Interdisciplinary Perspectives on Infectious Diseases Volume 2013, Article ID 839456, 8 pages http://dx.doi.org/10.1155/2013/839456 Clinical Study Prospective Trial of a Novel Nomogram to Achieve Updated
More informationCystatin C: A New Approach to Improve Medication Dosing
Cystatin C: A New Approach to Improve Medication Dosing Erin Frazee Barreto, PharmD, MSc, FCCM Assistant Professor of Pharmacy and Medicine Kern Scholar, Center for the Science of Health Care Delivery
More informationEvaluation of Vancomycin Continuous Infusion in Trauma Patients
OBJECTIVES Evaluation of Vancomycin Continuous Infusion in Trauma Patients Brittany D. Bissell, Pharm.D. PGY-2 Critical Care Pharmacy Resident Jackson Memorial Hospital Miami, Florida Evaluate the potential
More informationTrust Guideline. for Ciclosporin Treatment & Monitoring for Adult* Patients with Acute, Severe Ulcerative Colitis. (*ie aged 16 years and over)
Trust Guideline for Ciclosporin Treatment & Monitoring for Adult* Patients with Acute, Severe Ulcerative Colitis (*ie aged 16 years and over) abc A guideline recommended for use In: Gastroenterology/Medical
More informationAdult Dose. Adults Day 1: 1mg/kg daily Day 2: 2mg/kg daily Day 3 onwards: 3mg/kg daily. Where appropriate consider rounding dose to nearest 50mg.
AMIKACIN All ages>1month: 30mg/kg daily 1.5g once daily IV infusion over 30-60 Monitor renal function before treatment and weekly. Caution if used with other nephrotoxic drugs. Levels required. Trough
More informationCLINICAL GUIDELINE FOR MANAGEMENT OF NEUTROPENIC SEPSIS IN ADULT CANCER PATIENTS (this guideline excludes haematology patients)
CLINICAL GUIDELINE FOR MANAGEMENT OF NEUTROPENIC SEPSIS IN ADULT CANCER PATIENTS (this guideline excludes haematology patients) 1. Aim/Purpose of this Guideline 1.1. Systemic cancer treatments and immunological
More informationEssential Shared Care Agreement: Lithium
Ref No. E042 Essential Shared Care Agreement: Lithium Please complete the following details: Patient s name, address, date of birth Treatment (indication, dose regimen, brand name) Monitoring (proposed
More informationManaging Hyperglycaemia in Acute (Adult) Inpatients Requiring Enteral Feeding Guidelines
Document Control Title Managing Hyperglycaemia in Acute (Adult) Inpatients Requiring Author Author s job title Specialist Nurse Consultant Physician Department Directorate Unscheduled Care Version Date
More informationInvestigating for Urinary Tract Infection in Patients Undergoing Hip and Knee Replacement Surgery A Clinical Guideline recommended
A Clinical Guideline recommended For use in: By: For: Division responsible for document: Key words: Name of document authors: Job titles of document authors: Name of document author s Line Manager: Job
More informationJoint Trust Guidelines for Management of Central Venous Catheter Infection in Children Receiving Parenteral Nutrition
For Use in: By: For: Key words: Name of document author: Job title of document author: Name of document author s Line Manager: Job title of author s Line Manager: Supported by: Children s services, Neonatal
More informationManagement of Catheter Related Bloodstream Infection (CRBSI), including Antibiotic Lock Therapy.
Management of Catheter Related Bloodstream Infection (CRBSI), including Antibiotic Lock Therapy. Written by: Dr K Gajee, Consultant Microbiologist Date: June 2017 Approved by: Drugs & Therapeutics Committee
More informationTrust Guideline for the management of Parapneumonic Effusion in children
A clinical guideline recommended for use For Use in: By: For: Division responsible for document: Buxton ward, Children s Assessment Unit (CAU) All staff Children with parapneumonic effusion Women and Children
More informationIndex No: MMG11/1. Version: 1. Date ratified: 12 th November 2013
Index No: Intravenous fluid prescription in children For previously well children aged one month to 16 years (excluding renal, cardiac, diabetic ketoacidosis and acute burns patients) Version: 1 Date ratified:
More informationClarity around the new editions of the BNF Publications
Clarity around the new editions of the BNF Publications UKMi, the Neonatal and Paediatrics Pharmacy Group (NPPG) and the BNF are aware of a number of discussions and email threads discussing BNF for Children
More informationTrust Guideline on Routine Oxygen Saturation Measurement on the New-born (Pulse Oximetry)
Trust Guideline on Routine Oxygen Saturation Measurement on the New-born For Use in: By: For: Division responsible for document: Key words: Name and job title of document author: Name and job title of
More informationHERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) DABIGATRAN RECOMMENDED What it is Indications Date decision last revised
Name: generic (trade) Dabigatran etexilate (Pradaxa ) HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) DABIGATRAN RECOMMENDED What it is Indications Date decision last revised Direct thrombin inhibitor
More informationClinical Safety & Effectiveness Cohort # 10
1 Clinical Safety & Effectiveness Cohort # 10 Improving Weight-Based Vancomycin Dosing and Monitoring DATE Educating for Quality Improvement & Patient Safety 2 Financial Disclosure lizabeth A. Walter,
More informationIntravenous Vancomycin Use in Adults Intermittent (Pulsed) Infusion
Intravenus Vancmycin Use in Adults Intermittent (Pulsed) Infusin Backgrund This plicy cvers the use f intravenus vancmycin prescribed as an intermittent (pulsed) infusin. This can be used fr treatment
More informationModifying Drug Dosing for Patients with Renal Insufficiency
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/focus-on-pharmacy/modifying-drug-dosing-for-patients-with-renalinsufficiency/3427/
More informationEMPIRICAL PRESCRIBING GUIDELINES FOR SYSTEMIC FUNGAL INFECTIONS IN ADULTS - HH (1)/CL(G)/651/13
Hampshire Hospitals NHS Foundation Trust Empirical Antifungal Prescribing Guidelines [INSERT UNIQUE POLICY IDENTIFIER] Due for latest review on January 2015. CHECK THE INTRANET FOR LATEST VERSION EMPIRICAL
More informationprophylaxis for endocarditis in patients at high risk prophylaxis for major surgical procedures
1 Glycopeptides appropriate uses serious infections due to beta-lactam- resistant gram-positive microorganisms infections due to gram-positive microorganisms in patients with serious allergy to beta-lactam
More informationAntimicrobial Management of Febrile Neutropenic Sepsis
Antimicrobial Management of Febrile Neutropenic Sepsis Written by: Dr J Joseph, Consultant Haematologist Dr K Gajee, Consultant Microbiologist Amended by: Larissa Claybourn, Antimicrobial Pharmacist Date:
More informationContributes to CQC Outcome number: 9&12 Consulted With Post/Committee/Group Date. Pharmacist. Alison Felton Head of Pharmacy/Deputy Chief.
Prescribing paracetamol in adult inpatients at MEHT Type: Clinical Guideline Register No: 18005 Status: Public on ratification Developed in response to: In line with Basildon Contributes to CQC Outcome
More informationInfections Amenable to OPAT. (Nabin Shrestha + Ajay Mathur)
3 Infections Amenable to OPAT (Nabin Shrestha + Ajay Mathur) Decisions regarding outpatient treatment of infections vary with the institution, the prescribing physician, the individual patient s condition
More informationMEDICATION MONITORING: Pharmacist-Managed Intravenous (IV) Vancomycin Protocol
I. PURPOSE MEDICATION MONITORING: Pharmacist-Managed Intravenous (IV) Vancomycin Protocol To allow standardized pharmacist management of IV vancomycin in the inpatient setting using evidence-based guidelines
More informationNCCP Chemotherapy Regimen. Carboplatin (AUC 2) Weekly with Radiotherapy (RT)
INDICATIONS FOR USE: Carboplatin (AUC 2) Weekly with Radiotherapy (RT) Regimen Code 00419a *Reimbursement Indicator INDICATION ICD10 Chemoradiation treatment for stage III and IV locally advanced C11 nasopharyngeal
More informationJoint Trust Guideline for the Management of: CFS/ME (Chronic Fatigue Syndrome / Myalgic Encephalopathy) in Children and Young People
A Clinical Guideline For Use in: By: For: Division responsible for document: Key words: Name of document author: Job title of document author: Name of document author s Line Manager: Job title of author
More informationIntravenous Vancomycin Use in Adults Intermittent (Pulsed) Infusion
Backgrund This plicy cvers the use f intravenus vancmycin prescribed as an intermittent (pulsed) infusin. This can be used fr treatment r prphylaxis. Evidence supprting this guidance is detailed belw.
More informationCardiac Catheter Labs Intravenous Drug Therapy Guide
Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc) Contact Name and Job Title (author) Cardiac Catheter Lab IV Medicines Guideline Helen Buxton ( Senior Cath Lab
More informationPaediatric Prescribing Pocket Guide September 2014 (Version 1)
PAGE 1 Paediatric Prescribing Pocket Guide September 2014 (Version 1) In children, the risk of medication errors is often exacerbated by the need for calculations to determine the dose. Prescribing errors
More informationIntroduction The Role of the Kidneys Drugs used in Renal Disease Drugs and Dialysis Renal Pharmacy Team
Introduction The Role of the Kidneys Drugs used in Renal Disease Drugs and Dialysis Renal Pharmacy Team Drugs play a major role in both treating and causing renal disease Doses of some drugs need to be
More informationTrust Guideline for Capillary Blood Ketone Monitoring For Inpatients with Diabetes Mellitus Over 16 Years of Age
For Use in: By: For: Division responsible for document: Key words: Name and job title of document authors: Name and job title of document author s Line Manager: Supported by: All clinical areas of the
More informationViral Infections. 1. Prophylaxis management of patient exposed to Chickenpox:
This document covers: 1. Chickenpox post exposure prophylaxis 2. Chickenpox treatment in immunosuppressed/on treatment patients 3. Management of immunosuppressed exposed to Measles All children with suspected
More informationPRODUCT INFORMATION TARGOCID
NAME OF THE MEDICINE Non-proprietary Name teicoplanin PRODUCT INFORMATION TARGOCID DESCRIPTION Teicoplanin is a glycopeptide-antibiotic produced by Actinoplanes teichomyceticus. It is presented as a sterile,
More informationferric carboxymaltose 50mg iron/ml solution for injection/infusion (Ferinject ) SMC No. (463/08) Vifor Pharmaceuticals
ferric carboxymaltose 50mg iron/ml solution for injection/infusion (Ferinject ) SMC No. (463/08) Vifor Pharmaceuticals 17 December 2010 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationLRI Children s Hospital
Title: Prescribing in Cystic Fibrosis Page 1 of 10 LRI Children s Hospital Prescribing in Cystic Fibrosis Staff relevant to: Clinical staff working within the UHL Children s Hospital. Team & AWP approval
More informationPPP 1. Continuation, modification, and discontinuation of a medication
PRESCRIBING POLICIES: 4.7 PHARMACIST AUTHORITY The College of Pharmacists of BC Professional Practice Policy (PPP) 58 Medication Management (Adapting a Prescription) became effective April 1, 2009. The
More informationADULT (>16) ACUTE SICKLE PAIN GUIDELINE
ADULT (>16) ACUTE SICKLE PAIN GUIDELINE ID 2013 065 Author s Name Dr Anna Wood Author s Job Title Consultant Haematologist Division Consultant Haematologist Department Haematology Version number 3 Ratifying
More informationTrust Guideline for Management of Faltering Growth (Failure to Thrive) in Babies and Young Children.
Trust Guideline for Management of Faltering Growth (Failure to Thrive) in. A Clinical Guideline For use in: By: For: Division responsible for document: Women and Children Key words: Buxton Ward, Children
More informationAssessment of Therapeutic Drug Monitoring of Vancomycin in Elderly Patients According to New Guidelines
Original Article Clinical Chemistry Ann Lab Med 2014;34:1-6 http://dx.doi.org/10.3343/alm.2014.34.1.1 ISSN 2234-3806 eissn 2234-3814 Assessment of Therapeutic Drug Monitoring of Vancomycin in Elderly Patients
More information